Nov 19, 2020
Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection
Mar 09, 2020
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
Nov 07, 2019
New analysis of patients with autoimmune-related ILDs in the INBUILD study shown as poster presentation at the 2019 ACR/ARP Annual Meeting
Oct 10, 2019
FDA Grants Ofev® Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
Aug 05, 2019
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
Jul 25, 2019
FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD
May 20, 2019
Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD
Mar 18, 2019
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
Oct 11, 2018
FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction
Sep 26, 2018
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
Mar 29, 2018
New Large-Scale Trial Results Show Stiolto® Respimat® Prevents COPD Exacerbations Better Than Spiriva® Respimat®
Mar 19, 2018
FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
Mar 13, 2018
Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer
Jan 25, 2018
New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment
Jan 16, 2018
FDA approves new indication for Gilotrif® in EGFR mutation-positive NSCLC
Dec 12, 2017
Boehringer Ingelheim initiates real-world study of treatment sequencing in EGFR mutation-positive lung cancer
Nov 13, 2017
New RE-VERSE AD(TM) Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery
Oct 23, 2017
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Sep 11, 2017
Results from the INJOURNEY(TM) trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF
Jul 11, 2017
Final Phase III Study Results Reinforces Safety and Efficacy of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations